Vericel (VCEL) Tops Q3 EPS by 11c, Beats on Revenue; Offers FY25 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Vericel Reports Third Quarter 2025 Financial Results
November 6, 2025 7:55 AM ESTRecord Third Quarter Total Revenue of $67.5 Million
MACI Revenue Growth of 25% to $55.7 Million
Net Income of $5.1 Million and Adjusted EBITDA Margin of 25%
Record Third Quarter Operating Cash Flow of $22.1 Million
More than 800 MACI Arthro Surgeons Trained to Date
Conference Call Today at 8:30am Eastern Time
CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL), a leader in advanced therapies for the sports medicine and severe burn... More
